טוען...
Fulfilling the Promise of "Biased" G Protein–Coupled Receptor Agonism
The fact that over 30% of current pharmaceuticals target heptahelical G protein–coupled receptors (GPCRs) attests to their tractability as drug targets. Although GPCR drug development has traditionally focused on conventional agonists and antagonists, the growing appreciation that GPCRs mediate phys...
שמור ב:
| הוצא לאור ב: | Mol Pharmacol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The American Society for Pharmacology and Experimental Therapeutics
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4551052/ https://ncbi.nlm.nih.gov/pubmed/26134495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.115.099630 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|